EDAP TMS S.A. Announces Initial Ablatherm-HIFU Treatments At Premiere M. D. Anderson Cancer Center in Ongoing Phase II/III Clinical Trial

LYON, France, July 17, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that urologists at the University of Texas M.D. Anderson Cancer Center have treated their first two localized prostate cancer patients with Ablatherm-HIFU (high intensity focused ultrasound). The prestigious center is one of 13 Ablatherm sites participating in ENLIGHT, EDAP's ongoing Phase II/III clinical trial to evaluate the minimally invasive, robotized treatment in patients with localized prostate cancer.